01 · Start here
Understand the condition and your first steps.
A practical orientation for patients and families, including the questions worth bringing to a kidney specialist.
Read the patient guide →Evidence-first ADPKD guide
Make the next care decision clearer.
Plain-language guidance for treatment, symptoms, daily life, and research, with a clear line between established care and what is still uncertain.
What matters now
- Tolvaptan remains the strongest established disease-modifying therapy in appropriate high-risk adults.
- Risk-stratified care and supportive management remain foundational.
- No cure is clinically proven in humans.
02 · Treatment
Separate established care from promising research.
Tolvaptan, blood pressure, monitoring, and strategies ranked by the strength of evidence.
Explore treatment →03 · Daily life
Use practical guidance for the everyday questions.
Food, hydration, activity, symptoms, and the points where individualized medical advice matters.
Go to daily life →Research watch
Follow trials without the hype.
Priority trials, cure research, and recent human evidence in one place.
View research and trials →Evidence log
Latest tracked movement
- Guideline corrections: Rechecked the KDIGO 2025 ADPKD guideline for blood pressure targets, tolvaptan eligibility, hydration, metformin, and SGLT2 inhibitor guidance.
- ClinicalTrials.gov refresh: Refreshed every NCT identifier in `DATA/trials.csv` against the live registry.
- PubMed review: Screened 159 PubMed records dated 2026-06-01 through 2026-08-24 for ADPKD relevance.